KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned a consensus recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $25.00.

Several equities analysts have weighed in on the company. Bank of America began coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. TD Cowen began coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th.

KalVista Pharmaceuticals Stock Performance

KALV opened at $8.77 on Friday. The company has a 50 day moving average of $8.86 and a 200 day moving average of $10.94. The company has a market cap of $433.41 million, a PE ratio of -2.41 and a beta of 0.86. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. Research analysts forecast that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the sale, the insider now directly owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,627 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the transaction, the chief executive officer now directly owns 274,596 shares in the company, valued at approximately $2,677,311. The trade was a 2.70 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares in the last quarter. SG Americas Securities LLC grew its position in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $634,000. JPMorgan Chase & Co. lifted its holdings in KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after acquiring an additional 1,670 shares during the period. Finally, Barclays PLC increased its position in shares of KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 54,257 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).